Annovis Bio, Inc. (ANVS)

Market Cap	40.57M
Revenue (ttm)	n/a
Net Income (ttm)	-40.94M
Shares Out	19.05M
EPS (ttm)	-3.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	381,221
Open	2.250
Previous Close	2.230
Day's Range	2.110 - 2.269
52-Week Range	2.080 - 20.000
Beta	1.63
Analysts	Strong Buy
Price Target	31.40 (+1,374.18%)
Earnings Date	Mar 31, 2025

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 29, 2020
• Employees: 16
• Stock Exchange: NYSE
• Ticker Symbol: ANVS
• Website: https://www.annovisbio.com

Analyst Forecast

According to 6 analysts, the average rating for ANVS stock is "Strong Buy." The 12-month stock price forecast is $31.4, which is an increase of 1,374.18% from the latest price.

Price Target

$31.4

(1,374.18% upside)

Analyst Consensus: Strong Buy